The Medicines Company sales fall 28.6% quarter-on-quarter

5 May 2015

US pharma firm The Medicines Company (Nasdaq: MDCO) reported a 28.6% fall in quarterly revenue for the first quarter of 2015 on a year-on-year basis.

Worldwide net revenue decreased from $177.2 million in the first quarter of 2014 to $126.5 million in the first quarter of this year, which also compared negatively with the consensus estimate of $138.8 million.

Adjusted net income for the first quarter of 2015 was $5.7 million, or $0.08 per share. In the same quarter last year, The Medicines Company posted earnings per share of $0.33 and adjusted net income of $22.1 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK